Ascletis Initiates U.S. Phase I Study Of Oral ASC36 For Obesity

Ascletis Pharma initiated a U.S. Phase I trial for ASC36, an oral amylin receptor peptide agonist being developed to treat obesity, after receiving FDA Investigational New Drug clearance. The clearance advances ASC36 into human clinical development and provides a positive regulatory milestone for Ascletis, though efficacy and commercial potential remain unproven at the early-stage trial phase.